Doximity: Network Effects, Normalizing Pharma Budgets, and Undemanding Valuation Create an Attractive Buy Opportunity

In a report released yesterday, Richard Close from Canaccord Genuity upgraded Doximity to a Buy, with a price target of $34.00.

Richard Close has given his Buy rating due to a combination of factors tied to valuation, business fundamentals, and market overreaction. He argues that the sharp share-price decline after the latest quarterly results reflects excessive pessimism about near-term pharma marketing budgets and AI-related risks, while the long-term outlook remains intact as policy and pricing uncertainties ease and budgets normalize.

He also emphasizes Doximity’s strong network effects and trust-based moat, with exceptionally high clinician adoption and rigorous expert validation of its AI tools, already embraced by over 100 leading health systems. Combined with management’s confidence in returning to double-digit revenue growth as pharma spending rebounds, and an undemanding multiple on revenue, EBITDA, and free cash flow for a “Rule of 50–60” business, Close concludes the stock offers an attractive risk‑reward profile at current levels.

In another report released on February 7, TipRanks – Google also upgraded the stock to a Buy with a $31.00 price target.